close

Enter

Log in using OpenID

Rare Disease Treatment Market Expected to Value US$ 78,434 Million By 2025

embed
The public is aware of these rare diseases and this awareness is rising owing to government effort and other social groups. Adding to this scenario, the reimbursement schemes in developed economies are pushing the growth in demand for rare disease t
North America to Remain Dominant in the Global Rare Disease
Treatment Market over the Forecast Period
A comprehensive evaluation presented by Persistence Market Research on the global
rare disease treatment market in a new research report titled “Rare Disease Treatment
Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025” highlights
the performance of the various segments in the market over a period of eight years.
This involves the current scenario of the market dynamics along with the forecast of
the entire market across various geographies. According to Persistence Market
Research, there are many opportunities that promote revenue growth in this market
during the forecast period.
The report covers important geographies of North America, Latin America, Europe,
Asia Pacific and Middle East and Africa. Of these major landscapes, North America
lays a significant growth track to show a value of US$ 78,434 Mn by the end of 2025
according to forecast insights in the research study. Following North America, Europe
and Asia Pacific, especially Japan, are in line showing potential for the treatment of
rare diseases over the period of eight years. The Middle East and Africa region
(MEA) will depict sluggish growth owing to low awareness of rare diseases and
hence their treatments.
Request to view table of content @
http://www.persistencemarketresearch.com/market-research/rare-diseasetreatment-market/toc
Several opportunities lurk around the market, creating a positive impact on global
market growth rate
Acquisitions across the global scenario can be used to expand the business portfolio
and operations of key players, who will do well to leverage this strategy to establish a
global footprint. Forward integration can be achieved by expanding the value chain.
The operating efficiency should be increased to achieve high return on investment.
This can be achieved by shifting the manufacturing of important medicines to orphan
drugs. The manufacturers of orphan drugs are enjoying the advantages of tax benefits,
fast approvals and other research grants, thereby making room for more innovations.
Product innovation can lead to advanced therapeutics and innovations in medicine or
drugs, which can be used to tap new markets. Moreover, the increasing incidence of
rare diseases gives a plus to the market. The public is aware of these rare diseases and
this awareness is rising owing to government effort and other social groups. Adding
to this scenario, the reimbursement schemes in developed economies are pushing the
growth in demand for rare disease treatments and thereby fueling the rare disease
treatment market growth in developed countries.
A sample of this report is available upon request @
http://www.persistencemarketresearch.com/samples/12862
Global Rare Disease Treatment Market: Segmental Forecast
The global rare disease treatment market report involves a five level segmentation
comprising – by therapeutic area, by drug type, by drug class, by mode of
administration and by distribution channel.
The genetic diseases segment by therapeutic area, which was dominating the global
market in the past will show similar traction in the next eight years. This segment is
anticipated to be valued at US$ 56,241 Mn by the end of 2025. The metabolic
diseases segment by therapeutic type shows higher growth rate as compared to the
genetic disease segment and is poised to reach a value of US$ 23,938 Mn by 2025
end
By drug type, originator drugs is the largest segment in the global rare disease
treatment market, estimated to hold about 75% market share by 2025 end
Of the various drug class segments, organic compounds is the dominant and most
attractive segment, with attractiveness index of 0.6 during the forecast period
The oral segment by mode of administration dominates the global market for rare
disease treatment from a revenue standpoint and is forecasted to continue this trait
throughout the period of forecast. It has the highest market attractiveness index of
2.2. The injectable segment is poised to account for a value share of 39.5% by 2025
end and reflects a market attractiveness index of 0.8
By distribution channel, specialty pharmacies segment dominated the global rare
disease treatment market in revenue terms in 2016 and is projected to continue to do
so throughout the forecast period. Specialty pharmacies is the most attractive
segment, with attractiveness index of 1.6 during the forecast period
Competitive Intelligence – Key Player Analysis
The research report on the global rare disease treatment market profiles key players in
the market and their complete intelligence including facts such as product portfolio,
strategies, geographical spread, etc. Some of the key players involved are Novartis
AG, Pfizer, F. Hoffmann-La Roche Ltd., Celgene Corporation, AbbVie Inc., Johnson
& Johnson Services, Inc., Shire, Alexion, Novo Nordisk A/S, Sanofi, Bayer AG,
Amgen, Inc., Allergan plc., Eisai Co. Ltd., Bristol-Myers Squibb Company, Merck &
Co., Inc., Vertex Pharmaceuticals, Baxter, BioMarin and Teva Pharmaceutical
Industries Ltd.
Browse Complete Report @
http://www.persistencemarketresearch.com/market-research/rare-diseasetreatment-market.asp
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our
research model is a unique collaboration of data analytics and market research
methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and
customer experience analytics, we deliver business intelligence for
organizations of all sizes.
Our offerings include pre-built reports that address every major sale,
customized solutions to cater to client-specific needs, and consulting services to
offer more value addition. Our next-generation research approach for exploring
emerging technologies has allowed us to solve the most complex problems of
clients. We do not follow a reactive approach, but a pro-active one. Expert
analysts at PMR keep a tab on next-generation technologies in their R&D phase
and provide the latest insights into these technologies when they are being
commercialized. Our ground-breaking approach allows us to deliver market
solutions before the technologies reach the market.
Our client success stories feature a range of clients from Fortune 500 companies
to fast-growing startups. PMR’s collaborative environment is committed to
building industry-specific solutions by transforming data from multiple streams
into a strategic asset.
Contact Us:
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
Tel: +1-646-568-7751
Email: [email protected]
Website: http://www.persistencemarketresearch.com/
[email protected]
Stay updated with our official Blog: http://pmrblog.com
1/--pages
Report inappropriate content